China News Service, October 20, Liu Jingzhen, Chairman and Secretary of the Party Committee of Sinopharm Group, responded on the 20th on the latest research progress of the new crown inactivated vaccine.
He said that after the safety and protection data are obtained in the phase III clinical trial, the vaccine can be marketed after review and approval.
In fact, emergency use has already begun.
Data map: Researchers are demonstrating the experimental process of the new coronavirus vaccine development.
Photo by Tang Yanjun
The State Council’s Joint Prevention and Control Mechanism held a press conference on the 20th. At the meeting, a reporter asked questions about the latest research progress of inactivated vaccines. When will the general public receive the new crown inactivated vaccine?
Liu Jingzhen responded that at present, the two inactivated vaccines, Beijing Institute of Biological Products and Wuhan Institute of Biological Products, which are affiliated to Sinopharm Group, are currently undergoing phase III clinical trials in ten countries including the UAE, Paris, Jordan, Peru, Argentina, and Egypt. In the trial, more than 50,000 people have been vaccinated, and the total number of vaccinators will reach more than 60,000.
The current response is still very good. The sample size of the vaccinated population covers 125 nationalities, leading the world in progress in all aspects, and is widely recognized internationally.
Now dozens of countries have put forward new crown vaccine requirements to Sinopharm Group Sino Biotech.
Liu Jingzhen introduced that on February 1, Sinopharm, as the lead unit, won the emergency approval of the key special inactivated vaccine project of the Ministry of Science and Technology National Key R&D Program "Public Safety Risk Prevention and Control and Emergency Technology and Equipment".
On April 12, the new crown inactivated vaccine developed by the Wuhan Institute of Biological Products was approved for clinical trials, and domestic phase I/II clinical trials were carried out simultaneously.
On April 27, the inactivated new crown vaccine developed by the Beijing Institute of Biological Products was again approved for clinical trials, adding double insurance to the development of the new crown vaccine.
In the domestic phase I/II clinical study, a total of 4064 people of each age group were included in the group. The unblinded results showed that the safety after vaccination was good. Different ages, different procedures, and different doses of vaccination all produced high titer immune responses. After two doses of the vaccine were inoculated according to the procedure of 0 and 28 days, the positive conversion rate of neutralizing antibodies reached 100%.
Liu Jingzhen pointed out that the current new crown inactivated vaccine is in the full sprint stage. Sinopharm China's biological vaccine research and development is the last kilometer of the long march. After the safety and protection data of the phase III clinical trial is obtained, the vaccine can be reviewed and approved. Listed. In fact, emergency use has already begun. Both of the two inactivated vaccines of Sinopharm Sino Biotech have been included in the scope of emergency use. At present, China National Biotech is ready for large-scale production. The two new crown vaccine P3 production plants of Beijing Institute of Biological Products and Wuhan Institute of Biological Products have been completed. The production capacity will reach 1 billion doses next year, which can ensure a safe and sufficient vaccine supply. .